Scalper1 News
Big pharma Merck (MRK) will study its hot new immunotherapy drug candidate in combination with rival Pfizer’s currently approved Xalkori to treat metastatic lung cancer, the two firms announced Tuesday. The trial of pembrolizumab and Xalkori, expected to start next year, is “just one example of the willingness of sponsors to work together in an effort to accelerate progress against some of the most difficult-to-treat cancers,” said Pfizer Chief Scalper1 News
Scalper1 News